Sharpe ratio
0.95Return earned for the risk taken.
Moderate
Moderate risk-adjusted returns. The reward for risk has been average.
+19.68%1Y Absolute Return
-0.24%1D
Loading NAV history…
Past performance is not an indicator of future returns.
Returns calculator comparison
Compare an illustrative investment outcome across return assumptions.
| Asset | Projected corpus | Total invested | Gain | Annual return |
|---|---|---|---|---|
| Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-GrowthFund 5Y annualised return | ₹10,90,045 | ₹7,32,612 | ₹3,57,433 | +15.90% |
| EPFIllustrative annual assumption | ₹8,95,132 | ₹7,32,612 | ₹1,62,520 | +8.25% |
| Residential propertyIllustrative annual assumption | ₹8,67,662 | ₹7,32,612 | ₹1,35,050 | +7.00% |
| PPFIllustrative annual assumption | ₹8,69,819 | ₹7,32,612 | ₹1,37,207 | +7.10% |
| Bank fixed depositIllustrative annual assumption | ₹8,56,981 | ₹7,32,612 | ₹1,24,369 | +6.50% |
| GoldIllustrative annual assumption | ₹8,67,662 | ₹7,32,612 | ₹1,35,050 | +7.00% |
| Savings accountIllustrative annual assumption | ₹7,86,827 | ₹7,32,612 | ₹54,215 | +3.00% |
Illustration only. Fund results use the available NAV-derived annualised return and can be negative. Reference rows are assumptions, not current quoted rates or guaranteed returns; property excludes transaction costs, taxes, and liquidity constraints. Mutual fund investments are subject to market risk.
Wealth multiple
₹1 became₹1.21
₹1 Lakh since launch₹1.21 Lakh
Fund age7.3 yrs
Fund information
Scheme code147409
ISININF209KB1O25
BenchmarkBSE Healthcare TRI
CategoryEquity Scheme - Sectoral/ Thematic
Expense ratio1.05%
Exit loadExit load of 1% if redeemed within 30 days.
Minimum SIP₹100 SIP
Return comparison
63rd / 932 in category| Period | Fund | Benchmark | Category avg |
|---|---|---|---|
| 1M | +150.70% | — | — |
| 3M | +4.19% | — | — |
| 6M | +22.78% | — | — |
| 1Y | +19.68% | — | +4.16% |
| 3Y | +20.72% | — | +12.54% |
| 5Y | +15.90% | — | +10.04% |
| Since Launch | +21.21% | — | — |
Risk-adjusted performance
Every measure is expanded with a plain-language reading of the latest calculated value.
Sortino ratio
1.41Return earned while limiting downside risk.
Good
Good downside protection with strong returns.
Standard deviation
12.55%How much the fund’s returns fluctuate over time.
Moderate volatility
Returns can move up and down noticeably.
Beta
—How closely the fund moves with the market.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Alpha
—Extra return generated above the benchmark.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Treynor ratio
—Return earned for each unit of market risk taken.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Calmar ratio
1.04How well the fund rewarded investors relative to its biggest decline.
Excellent
Excellent balance between returns and drawdowns.
Information ratio
—How consistently the fund outperformed its benchmark.
Unavailable
This measure needs sufficient fund and benchmark history to calculate.
Portfolio allocation
Latest disclosed portfolio mix
Asset allocation
Allocation data has not been disclosed.
Market cap allocation
Sector allocation
Equity exposure by sector
Top holdings
10 of 40 disclosed positions
| Holding | Sector | Instrument type | Weight |
|---|---|---|---|
| Torrent Pharmaceuticals Ltd | Healthcare | Equity | 9.9351% |
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 9.7514% |
| Apollo Hospitals Enterprise Ltd | Healthcare | Equity | 7.0845% |
| Cipla Ltd | Healthcare | Equity | 4.556% |
| Aurobindo Pharma Ltd | Healthcare | Equity | 4.2859% |
| Ajanta Pharma Ltd | Healthcare | Equity | 4.1728% |
| Sai Life Sciences Ltd. | Healthcare | Equity | 3.8852% |
| Mankind Pharma Ltd. | Healthcare | Equity | 3.5778% |
| Lupin Ltd | Healthcare | Equity | 3.5131% |
| Abbott India Ltd | Healthcare | Equity | 3.3481% |
Fund management
DH
Dhaval Shah
Since 2019 · Prior to joining Aditya Birla Sunlife Mutual Fund he has worked with HDFC Mutual Fund, Reliance Mutual Fund, Morgan Stanley.
Mr.Shah has done B.Com. from University of Mumbai & MBA from Somaiya Institute of Management Studies & Research. He also holds CFA designation.
Compare similar funds
No comparable category funds are available yet.
Summary
A high-risk equity scheme - sectoral/ thematic fund. Ahead of its category average over 3Y by 8.2 points. Healthcare makes up 96% — trouble in that sector hits the whole fund.
Strengths
- Ahead of its category average over 3Y by 8.2 points.
- Turned every ₹1 into ₹4.1 since launch — compounding at 21.2% a year.
- Same fund manager for 7+ years — the strategy has not chopped and changed.
- Ranks 63 of 932 in its category over 1 year.
Weaknesses
- None
Ideal investor
- Needs a 5–7+ years horizon to ride out its high risk level.
- Good fit for SIPs — spreading purchases smooths out 12.6% volatility.
Risk drivers
- Healthcare makes up 96% — trouble in that sector hits the whole fund.